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Background: Mineral water from deep-sea bedrock, formed over thousands of years, is rich in minerals such as Ca,
Mg, Na, K, Fe and others. Our present study was to investigate the preventive effects of natural deep-sea water on
developing atopic dermatitis (AD).
Methods: We elicited AD by application of DNCB (2,4-dinitro-chlorobezene) in Nc/Nga mouse dorsal skin. Deep Sea
water (DSW) was filtered and concentrated by a nanofiltration process and reverse osmosis. We applied
concentrated DSW (CDSW) to lesions five times per week for six weeks, followed by evaluation. 1% pimecrolimus
ointment was used as positive control. The severity of skin lesions was assessed macroscopically and histologically.
Levels of inflammatory mediators and cytokines in the serum were detected by Enzyme-linked immunosorbent
assay (ELISA) and the levels of CD4+ and CD8+ spleen lymphocytes were determined by flow cytometry analysis.
Results: DNCB-treated mice showed atopic dermatitis-like skin lesions. Treatment of mice with CDSW reduced the
severity of symptoms in the skin lesions, including edema, erythema, dryness, itching, and transepidermal water loss
(TEWL). Histological analyses demonstrated that epidermal thickness and infiltration of inflammatory cells were
decreased after CDSW treatment. Given these interesting observations, we further evaluated the effect of CDSW on
immune responses in this AD model. Treatment AD mice with CDSW inhibited up-regulation of IgE, histamine, and
pro-inflammatory cytokines in the serum. Also, the CD4+/CD8+ ratio in spleen lymphocyte was down-regulated
after treatment with CDSW. Finally, cytokines, especially IL-4 and IL-10 which are important for Th2 cell
development, were reduced.
Conclusions: Our data suggests that topical application of CDSW could be useful in preventing the development
of atopic dermatitis.Background
Mineral water from deep-sea bedrock is an attractive pro-
spect because it is rich in nutrients and minerals such as
Ca, Mg, Na, Zn, K, Fe, HCO3, Cl, SO4, NO3, etc. (Table 1)
[1]. Iron, in particular, is abundant in the deep-sea water
(DSW). Therefore, it seems to have an effect on the pre-
vention or treatment of anemia [2,3].
Atopic dermatitis (AD) is a chronic inflammatory skin
disease with symptoms of dryness and itchiness, in which* Correspondence: kimeh@semyung.ac.kr
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reproduction in any medium, provided the orrelapse is common [4,5]. The prevalence of AD has
increased 2–3 fold during the past three decades in indus-
trialized societies [5-9]. In the past a few years, it was
reported that pathogenesis of AD was related to a com-
plex interrelation of immunological, psychological, envir-
onmental and genetic factors [10]. AD skin lesions are
characterized by the presence of infiltrated inflammatory
cells such as eosinophils, monocytes, macrophages, mast
cells or T lymphocytes [11-14]. Several studies have been
performed to investigate cytokines, and reports show that
the generation of AD is elicited by a pathological defect,
such as cytokines from T-helper (Th) cells [15].
Th cells can be divided into two distinct groups in ac-
cordance with their cytokines; Th1 Th2 lymphocytes. In
AD patients’ blood, IL-4 and IL-5 concentration from Th2. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 The levels of elements in pre-DSW and CDSW












Na: sodium; Cl: chlorine; Ca: calcium; Mg: magnesium; K: potassium; Si: silicon;
Mn: manganese; Zn: zinc; Fe: iron Cu: copper; B: boron.
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pression was significantly up-regulated in atopic skin
lesions [16,17]. However, recent studies reported that Th1
response also plays an important role in AD disease [12].
In almost all chronic AD patients, up-regulation of the ex-
pression IFN-γ mRNA was also observed in atopic skin
lesions, whereas only a few chronic AD patients had
increases in the expression of IL-4 mRNA [18,19]. There-
fore, both Th1 and Th2 response contribute to the initi-
ation and maintenance of AD.
Treatment for AD has been studied using such drugs
based on steroids, anti-histaminic agents, and immuno-
suppressants [20]. However, there are many side effects
and limited therapeutic effects with long-term use [21].
Recently, it was reported that the application of minerals
has a therapeutic effect on the skin diseases [22-25].
Other studies reported that drinking mineral water or
exposure to mineral water at the spa affects the immune
system [1,26]. The effect of deep-sea water (DSW) on
atopic dermatitis is poorly understood. Therefore, we
wanted to demonstrate whether application of DSW to
atopic skin lesions has any beneficial effects for prevent-
ing atopic dermatitis in a mouse model for AD [27].
Methods
Chemicals and reagents
Natural deep-sea water (DSW) and concentrated DSW
(CDSW) were supplied by Jin Hae Resource Development
Inc. (Inchon, South Korea). The elemental composition of
DSW and CDSW were determined by inductively coupled
plasma mass spectrometry (ICP-MS). The mouse IgE
ELISA assay kit was from Koma Biotech (Seoul, Korea),
the mouse Th1/Th2 ELISA assay kit was from eBioscience
(San Diego, USA), and the IL-1β, IL-6 and TNF-α ELISA
assay kits were from R&D Systems (Minneapolis, MN,
USA). The CD4 (GK1.5) Alexa Fluor 488 and CD8 (2.43)PE antibodies were from Santa Cruz Biotechnology
(USA). Elidel (Novartis) is a 1% pimecrolimus topical solu-
tion and is an immunomodulating agent used for treating
eczema [28]. All other reagents were from Sigma-Aldrich
(St. Louis, MO, USA).
Desalted and concentrated DSW
Deep-sea water (DSW) was selectively filtered for sodium
chloride by nanofiltration and reverse osmosis. Desaliniza-
tion was performed by pre-processing with Hytrex Cart-
ridge Filter (Hytrex, USA), nano-filtration by SU-610
membrane (Toray, Japan), and reverse osmosis by SU-810
membrane (Toray, Japan), respectively (Additional file 1:
Figure S1). Concentrated DSW (CDSW) was nano-filtered
with SU-610 and evaporated (Additional file 2: Figure S2).
The elemental composition of DSW (Patent Number:
KR 10–0663084) and CDSW (Patent Number: KR 10–
0670474) are shown in Table 1, and were confirmed by
Korea Testing & Research Institute (KTR).
Animals
Six-week old male NC/Nga mice were from SLC Inc.
(Shizuoka, Japan). All experimental protocols were reviewed
and approved by the Animal Care Committee at Semyung
University (IACUC, protocol number: SMECAE 10-10-01).
The mice were house in a conventional laboratory condi-
tions with filtered air and consistent ambient temperature
(24±2°C), humidity (55±10%) and light (12 h light/dark
cycle). The mice were fed a non-purified pellet diet and tap
water ad libitum. Mice were divided into five groups
(n=10 per group) as follows: A, normal control; B, negative
control (DNCB); C, positive control (DNCB+1% pimecro-
limus); D, 2% CDSW treatment (DNCB+2% CDSW); and
E, 10% CDSW treatment (DNCB+10% CDSW).
DNCB-induced dermatitis
The experimental schedule for the preparation of AD-
like skin lesions in NC/Nga mice is summarized in
Additional file 3: Figure S3. The hair of dorsal skin of
mice was shaved under Zoletil 50 (50 mg/kg) and xyla-
zine (10 mg/kg) anaesthesia with a hair clipper 1 day be-
fore initial sensitization. On day 0, these mice were
sensitized by applying 200 μL of a solution containing 1%
DNCB in an acetone and olive oil mixture (3:1) to cause
AD-like skin lesions. After initial challenge, 0.4% DNCB
solution was repeatedly applied to the same area of the
skin for 12 times at 3 day intervals. 200 μL of test samples
(DW, 2% CDSW, 10% CDSW, 1% pimecrolimus) were ap-
plied to the dorsal skin every day (p.m. 2:00~3:00).
The clinical skin severity
The clinical skin severity was evaluated once per week
(a.m. 10:00~11:00) by the following scoring procedure;
0 (none), 1 (mild), 2 (moderate), 3 (severe) for each of the
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thema, edema, excoriation/erosion, and scaling/dryness
[28]. Itch was assessed by their behavior in 1 hour, and
scaling/dryness by content of moisture in the epidermis
using Corneometer CM825 (Courage and Khazaka Elec-
tronic Co., Germany). Erythema, edema, and excoriation/
erosion were evaluated macroscopically.
Measurement of transepidermal water loss on the dorsal skin
The hair on the dorsal skin of each mouse was shaved
using an hair clipper under Zoletil 50 (50 mg/kg) and
xylazine (10 mg/kg) anesthesia and TEWL was measured
using a Tewameter TM300 (Courage and Khazaka Elec-
tronic Co., Germany) at 0, 1, 2, 3, 4, 5 and 6 weeks. The
values were recorded when stabilized approximately 10 s
after the probe had been placed on the skin.
Histological analysis
Skin tissue was isolated from each group of mice and fixed
with 10% 50 mM PFA in phosphate buffer (pH 7.0) for 24
hours at 4°C. Eight micrometer-thick sections of dorsal
skin were stained with hematoxylin and eosin (H&E) and
observed by optical microscopy (Evos Xl, USA). The sec-
tions were examined for the presence and degree of in-
crustation, thickness of the epidermis, epidermal necrosis,
bleeding, hyperkeratosis and inflammation. Epidermal
thickness was measured by Micron (EVOS, v2.0) a digital
imaging software.
Measurement of blood parameters
On the sixth week, the mice were sacrificed, blood was
collected from the heart, and the spleen was dissected.
The total IgE and histamine levels in the serum were mea-
sured by ELISA. Levels of inflammatory cytokines (IL-1β,
IL-6 and TNF-α)and Th cell development cytokines (IL-2,
IL-4, IL-10 and IFN-γ) in the serum also were determined
by ELISA. ELISA was performed according to the manu-
facturer’s instruction and quantitation was done with
SPECTRAMAX190 (Molecular Devices, USA).
Preparation of spleen lymphocytes
To analyze spleen lymphocytes, the spleens were cut into
pieces with a scissors in cold phosphate-buffered saline
(PBS) and homogenized with a glass homogenizer. Homo-
genized spleen was passed through strainer (BD, USA).
Spleen lymphocytes were isolated with Histopaque-1077
Hybri-Max (Sigma, USA) and centrifuged at 400 g for
twenty minutes. Lymphocytes were washed three times
with PBS. 10% fetal bovine serum (FBS)/phosphate-buffer
saline (PBS) was added to the spleen lymphocytes sus-
pended at 1 × 106 cells/ml with 5ml of either CD4-Alexa
Fluor 488 or CD8-PE monoclonal antibodies, and incu-
bated at 4°C for thirty minutes. The lymphocytes were
rinsed five times with PBS containing 10% FBS andcentrifuged at 1,200 rpm for five minutes. The stained
lymphocytes were fixed by 2% paraformaldehyde and
counted by FACSCalibur™ flow cytometry (BD Bioscience,
USA). Each analysis, including the control samples, was
based on at least 1 × 104 events exclusive of dead cells, and
gating on the basis of forward angle light scatter elimi-
nated residual erythrocytes [29].
Statistical analysis
Results are presented as mean± standard deviation (SD).
Data were analysed by one-way analysis of variance
(ANOVA) followed by Tukey’s test or Student’s t-test
(P< 0.05).
Results
Effect of CDSW on atopic skin lesions
We first examined whether DSW has any preventive effect
on atopic dermatitis. 1% pimecrolimus cream was used as
atopic dermatitis medicine [30] and by the treatment of
pimecrolimus, AD was prevented development signifi-
cantly as observed by histological analysis (Figure 1A).
DSW showed high salt concentration and maybe damage
to skin lesions. Therefore, we used concentrated deep sea
water (CDSW) that was desalted (Table 1). Interestingly,
the CDSW-treated mice recovered from atopic symptoms
in a concentration-dependent manner (Figure 1A). To
verify the effect of CDSW treatment on AD skin lesions,
we observed and scored skin symptoms including itching,
erythema, edema, excoriation/erosion and scaling/dryness
for six weeks (Figure 1B) [28]. After six weeks, the clinical
score of the DNCB-treated group increased significantly,
whereas the 1% pimecrolimus group was interfered with
development of AD. The CDSW-treated group also inhib-
ited increase of the clinical score, with the 10% CDSW-
treated mice significantly. The TEWL of the DNCB-
treated group was increased as time goes on. The 1%
pimecrolimus- and 10% CDSW-treated groups signifi-
cantly inhibited the increase of TEWL compared with the
DNCB-treated group from three weeks (Figure 2).
Recovery of skin tissue in atopic lesions by treatment of
CDSW
To further investigate the effect of CDSW on developing
AD skin lesions, we used H&E staining to examine
changes in epidermal thickness and reduced infiltration of
inflammatory cells in the dermatitis. DNCB-treated mice
had increased epidermal thickness that was restored to
normal levels by treatment with 1% pimecrolimus or 10%
CDSW (Figure 3). In addition, by means of histologic ana-
lysis, DNCB-elicited lesions showed increases in dermal
edema and infiltration of inflammatory cells in the dermis
when compared with the normal control group (Figure 4).
The skin lesions of 1% pimecrolimus-treated group were
prevented developing AD and were comparable to the
Figure 1 Effect of CDSW on development of AD-like skin lesions in DNCB-treated NC/Nga mice. A) The dorsal skin of mice were shaved
and were sensitized by DNCB; a. normal control, b. Negative control (DNCB), c. Positive control (DNCB+ 1% pimecrolimus), d. 2% CDSW-treated
(DNCB+ 2% CDSW) e. 10% CDSW-treated (DNCB+ 10% CDSW); (n = 10). The skin lesions recovered and B) the clinical score of DNCB-treated mice
was suppressed by the application of 10% CDSW (*p< 0.05).
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mice showed many symptoms of AD while the 10%
CDSW-treated showed much improvement. Thus, these
data indicate that treatment of CDSW to AD skin lesions
inhibited development of dermatitis induced by DNCB.
Effect of CDSW on DNCB induced allergic response
It was reported that the clinical severity of AD was asso-
ciated with up-regulation of serum IgE and histamineFigure 2 The effect of CDSW on TEWL in DNCB-treated NC/Nga
mice. The TEWL was measured every week for 6 weeks after
sensitization using Tewameter. Measurements were recorded when
TEWL reading were stabilized at 10 s after the probe was placed on
the skin. Data are presented as means ± SE (n = 10, *p< 0.05).levels. To access the effect of CDSW on allergic
responses, the serum from each group of mice were col-
lected and analysed. Repeated application of DNCB
caused an elevation of total IgE levels in the serum and
10% CDSW treatment significantly reduced this effect
(Figure 5). Also, we measured the release of histamine
which is downstream of IgE. Histamine levels were
increased significantly by DNCB treatment and the in-
hibitory effect of CDSW on DNCB-induced histamine
release was observed (Figure 5). CDSW inhibited
DNCB-induced total IgE levels and histamine release at
concentration-dependent manner. These results indicate
that CDSW lowers serum histamine and IgE levels in
DNCB induced murine AD model.
The inhibition of pro-inflammatory cytokines includ-
ing IL-1β, IL-6 and TNF-α is important characteristics
of anti-inflammatory activities; therefore, we examined
whether CDSW can inhibit expression of pro-cytokine
production. Secretion of pro-inflammatory cytokines,
TNF-α, IL-1β and IL-6, was increased markedly by
DNCB treatmet but CDSW inhibited the production of
cytokines (Figure 6).
T-cells have critical roles in the immune system and
include two major classes; CD4+ cells are helper cells
and CD8+ cells are suppressor cells [31]. CD4+ cells
lead the attack against pathogenic infections, and CD8+
cells lead to ending immune response. We found that
CDSW suppressed elevation of cutaneous inflammatory
cells number (Figure 4). To verify the effect of CDSW
on activation of inflammatory cells, we measured the
Figure 3 Change in skin epidermal thickness elicited by the repeated topical application of DNCB in NC/Nga mice. A) 8 μm-thick
sections of DNCB-treated mice were fixed with formaldehyde and stained with hematoxylin and eosin; a. normal control, b. negative control
(DNCB), c. positive control (DNCB+ 1% pimecrolimus), d. 2% CDSW-treated (DNCB+ 2% CDSW) e. 10% CDSW-treated (DNCB+ 10% CDSW); (n = 10,
magnification 200x, scale bars 200 μm). B) Epidermal thickness was measured by Micron (EVOS, v2.0) a digital imaging software (*p< 0.05).
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CD4+/CD8+ is 2.03 ± 0.362 in the normal control group
and increased (4.96 ± 0.685) in the DNCB-treated group.
However, 1% pimecrolimus ointment and 10% CDSW
significantly reduced the CD4+/CD8+ ratio induced by
DNCB (Table 2).
We also determined the expression of Th cell develop-
ment cytokines. IL-2 and IFN-γ, from Th1 cells did notshow significant change after DNCB-treatment or applica-
tion of CDSW (Figure 7A). Interestingly, IL-4 and IL-10
expression from Th2 cells were reduced significantly in
the 10% CDSW-treated group (Figure 7B). These results
were consistent with our macroscopic analysis and
histological data. In these experiments, treatment with
10% CDSW suppressed the enhanced allergic responses
induced by DNCB.
Figure 4 Histopathology of skin lesions in DNCB-treated NC/Nga mice after treatment with DNCB. Histopathological features of skin
lesions were fixed with formaldehyde and stained with hematoxylin and eosin; a. normal control, b. negative control (DNCB), c. positive control
(DNCB+ 1% pimecrolimus), d. 2% CDSW-treated (DNCB+ 2% CDSW) e. 10% CDSW-treated (DNCB+ 10% CDSW); (n = 10, magnification 200x, scale
bars 200 μm).
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Atopic dermatitis is one of the many diseases induced by
environmental elements as an antigen and the incidences
of AD have sharply increased recently [5-9]. AD is a com-
mon chronic inflammatory skin disease, although funda-
mental etiology and therapy is still poorly understood [6-
9]. Treatment with steroid-based drugs has been used for
treating AD, but has encountered some problems [21].
It is well known that Dead Sea water has beneficial
effects for treating skin diseases, including AD [32]. Re-
cent studies reported that Dead Sea water has been used
to treat psoriasis and atopic dry skin [32]. Dead Sea water
is rich in some minerals compared to ocean water. Miner-
als, are essential nutrients for human, can trigger altera-
tions on gene expression by initiating signaling events
upstream of gene transactivation. Until the present, thereare few studies for minerals and AD in human, however,
the studies of mice reported that Staphylococcus aureus
was increased on the skin of zinc-deficient mice before
the development of AD-like eruptions, leading the authors
to postulate that zinc may have an important role in the
induction of dermatitis [33]. The deficiency of magnesium
also induced AD-like skin lesions [34]. Because DSW also
has enough minerals as well as Dead Sea water, in the
present study, we demonstrate whether DSW also has an
effect on amelioration of AD-like skin.
Before application of DSW to DNCB-elicited lesions, we
screened the elemental composition of DSW and their
concentrations (Table 1). There were some potential pro-
blems because DSW had high sodium concentration and
salt-stress may induce inflammation [32]. Therefore, we
examined CDSW, which was made by concentrating and
Figure 5 CDSW inhibited IgE and histamine levels of DNCB-
sensitized NC/Nga mice. The serum prepared from heart in each
group mice (n = 10). A) Histamine and B) IgE levels in serum were
determined by ELISA as described in Materials and Methods. The
data represent the mean± S.D. of experiments performed in
triplicate (*p< 0.05).
Figure 6 Proinflammatory cytokine production by serum prepared fro
mice (n = 10). IL-1β, IL-6 and TNF-α levels in serum were determined by EL
experiments performed in triplicate (*p< 0.05).
Table 2 The levels of T cells from spleen
Group CD4+, % CD8+, % CD4+/CD8+, %
Normal control 3.45 ± 0.332a 1.62 ± 0.185 2.13 ± 0.153a′
DNCB 8.65 ± 0.455b 1.78 ± 0.267 4.96 ± 0.685b′
DNCB+ 1% pimecrolimus 3.87 ± 0.619a 1.66 ± 0.273 2.41 ± 0.533a′
DNCB+ 2% CDSW 8.15 ± 0.585b 1.76 ± 0.216 4.70 ± 0.627b′
DNCB+ 10% CDSW 4.25 ± 0.420a 1.67 ± 0.213 2.58 ± 0.404a′
CD4+ and CD8+ cells were from spleen and were determined by FACS
(fluorescence-activated cell sorter). Data are mean ± SEM of 10 mice. a-b, a′-b′
Values without the same superscript letter are significantly different at
P< 0.05.
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though the concentration of the other elements in CDSW
increased, the salt concentration was reduced (Table 1).
Accordingly, we examined whether CDSW has an effect
on AD induced by DNCB treatment in mice.
Although some symptoms of AD remained slightly, we
have shown that repeated application of 10% CDSW
improved the clinical severity score in DNCB-treated mice
compared with a negative control. We scored five symp-
toms in skin lesions including itching, erythema, edema,
excoriation/erosion and scaling/dryness to evaluate clin-
ical skin severity. Among the treated animals, the 10%
CDSW group had some edema, erosion and erythema,
and did not differ dramatically from the 2% CDSW group.
However, the itching was largely reduced by treatment
with 10% CDSW. We also measured we measured TEWL
and the moisture content in the epidermis and found that
the 10% CDSW group had significantly improved skin
barrier function and epidermis moisture. In addition, as
demonstrated by histologic analysis, the 10% CDSW treat-
ment reduced the infiltration of inflammatory cells, such
as leukocytes and mast cells. These findings suggest that
CDSW may restore skin barrier function.
Human AD disease is characterized by increased levels of
Immunoglobulin E (IgE) in the blood [35]. IgE plays anm NC/Nga mice. The serum prepared from hearts in each group of
ISA as described in Methods. The data represent the mean± S.D. of
Figure 7 Effect of CDSW on the levels of serum cytokine in DNCB-treated NC/Nga mice. The serum prepared from hearts in each group of
mice (n= 10). IL-2, IL-4, IL-10 and IFN-γ levels in serum were determined by ELISA as described in Methods. A) IL-2 and IFN-γ from Th1 lymphocytes
and B) IL-4 and IL-10 from Th2 lymphocytes. The data represent the mean±S.D. of experiments performed in triplicate (*p< 0.05).
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ciated with type-1 hypersensitivity. IgE is secreted from B
cells by external antigens such as pollen and house dust
mites [10,35]. Recent studies have reported that AD sever-
ity is related to an increase in total serum IgE levels [36,37].
Indeed, in our study, the clinical skin severity of DNCB-
induced dermatitis was increased in accordance with up-
regulation of total IgE levels in the serum. Mast cells are
one class of inflammatory cells and the activation and de-
granulation of mast cells is tightly regulated by IgE. Total
IgE affects mast cells and induces degranulation and
triggers secretion of histamine and other inflammatory
mediators [10,35,38]. Among the released inflammatory
mediators, histamine is one of the most potent mediators
[38]. In AD skin lesions, mast cells infiltrate the dermis and
elicit inflammation by releasing histamine and other media-
tors. Infiltration of inflammatory cells in the dermis,
induced by DNCB, was inhibited by 10% CDSW (Figure 4)
and significantly reduced total IgE and histamine levels
in the serum. These results indicate that CDSW lowers
serum histamine and IgE levels in DNCB induced murine
AD model.
It was believed that inflammatory cytokines contribute
to inflammation in skin lesions in AD [15]. T-helper cells(CD4+), a type of white blood cell, play an important role
in the immune system and have two subfamilies with dis-
tinct regulatory and influencing functions, based on their
cytokines: Th1 lymphocyte and Th2 lymphocyte [39]. Th1
lymphocytes produce IFN-γ and IL-2, while Th2 lympho-
cytes produce IL-4 and IL-10. Excessive release of these
cytokines is an important part of inflammation in AD.
Among these, it was reported that Th2 cytokines regulate
IgE synthesis. Treatment of DNCB promoted Th2 cell
responses, such as IL-4 and IL-10 production. Overex-
pressed IL-4 promotes the development of AD [40]. In
our experiments, production of IL-4 and IL-10 was
reduced by 10% CDSW treatment, which led to reduced
serum IgE levels. Treatment with 10% CDSW did not
have any significant effect on Th1 responses. Taken to-
gether, our data show that application of CDSW has a
beneficial effect for treating AD-like symptoms.
Conclusions
In conclusion, our data show that application of CDSW to
AD-like lesions significantly down-regulates Th2 cytokines,
serum IgE levels and clinical severity scores. These obser-
vations lead us to conclude that topical application of
CDSW to skin lesions alleviates at least some symptoms of
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of CDSW may prove to be an effective approach for pre-
venting other allergic skin diseases.
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